John Lamont
John Lamont
Professor of Medicine, Harvard Medical School
Verified email at
Cited by
Cited by
Clostridium difficile — More Difficult Than Ever
CP Kelly, JT LaMont
New England Journal of Medicine 359 (18), 1932-1940, 2008
Clostridium difficile colitis
CP Kelly, C Pothoulakis, JT LaMont
New England Journal of Medicine 330 (4), 257-262, 1994
Clostridium difficile Infection
DA Leffler, JT Lamont
New England Journal of Medicine 372 (16), 1539-1548, 2015
Choline, an essential nutrient for humans
SH Zeisel, KA Da Costa, PD Franklin, EA Alexander, JT Lamont, ...
The FASEB journal 5 (7), 2093-2098, 1991
Clostridium difficile infection
CP Kelly, JT LaMont
Annual review of medicine 49, 375, 1998
Saccharomyces boulardii Protease Inhibits the Effects of Clostridium difficile Toxins A and B in Human Colonic Mucosa
I Castagliuolo, MF Riegler, L Valenick, JT LaMont, C Pothoulakis
Infection and immunity 67 (1), 302-307, 1999
Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro.
M Riegler, R Sedivy, C Pothoulakis, G Hamilton, J Zacherl, G Bischof, ...
The Journal of clinical investigation 95 (5), 2004-2011, 1995
Mucin biophysics
R Bansil, E Stanley, JT LaMont
Annual review of physiology 57 (1), 635-657, 1995
Clostridium difficile toxin A perturbs cytoskeletal structure and tight junction permeability of cultured human intestinal epithelial monolayers.
G Hecht, C Pothoulakis, JT LaMont, JL Madara
The Journal of clinical investigation 82 (5), 1516-1524, 1988
Role of Gallbladder Mucus Hypersecretion in the Evolution of Cholesterol Gallstones: STUDIES IN THE PRAIRIE DOG
SP Lee, JT Lamont, MC Carey
The Journal of clinical investigation 67 (6), 1712-1723, 1981
Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum
C Pothoulakis, CP Kelly, MA Joshi, N Gao, CJ O'Keane, I Castagliuolo, ...
Gastroenterology 104 (4), 1108-1115, 1993
Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin
DYM Leung, CP Kelly, M Boguniewicz, C Pothoulakis, JT LaMont, ...
The Journal of pediatrics 118 (4), 633-637, 1991
Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum
I Castagliuolo, JT Lamont, ST Nikulasson, C Pothoulakis
Infection and immunity 64 (12), 5225-5232, 1996
Acute stress causes mucin release from rat colon: role of corticotropin releasing factor and mast cells
I Castagliuolo, JT Lamont, B Qiu, SM Fleming, KR Bhaskar, ...
American Journal of Physiology-Gastrointestinal and Liver Physiology 271 (5 …, 1996
Saccharomyces boulardii Stimulates Intestinal Immunoglobulin A Immune Response to Clostridium difficileToxin A in Mice
A Qamar, S Aboudola, M Warny, P Michetti, C Pothoulakis, JT LaMont, ...
Infection and immunity 69 (4), 2762-2765, 2001
Asymptomatic colonization by Clostridium difficile in infants: implications for disease in later life
S Jangi, JT Lamont
Journal of pediatric gastroenterology and nutrition 51 (1), 2-7, 2010
Intravenous immunoglobulin therapy for severe Clostridium difficile colitis
J Salcedo, S Keates, C Pothoulakis, M Warny, I Castagliuolo, JT LaMont, ...
Gut 41 (3), 366-370, 1997
Diminished Clostridium difficile toxin A sensitivity in newborn rabbit ileum is associated with decreased toxin A receptor.
R Eglow, C Pothoulakis, S Itzkowitz, EJ Israel, CJ O'keane, D Gong, ...
The Journal of clinical investigation 90 (3), 822-829, 1992
CP-96,345, a substance P antagonist, inhibits rat intestinal responses to Clostridium difficile toxin A but not cholera toxin.
C Pothoulakis, I Castagliuolo, JT Lamont, A Jaffer, JC O'Keane, ...
Proceedings of the National Academy of Sciences 91 (3), 947-951, 1994
Clostridium difficile infection: a worldwide disease
KE Burke, JT Lamont
Gut and liver 8 (1), 1, 2014
The system can't perform the operation now. Try again later.
Articles 1–20